NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science

Mitchell S. Cairo, Craig T. Jordan, Carlo Maley, Clifford Chao, Ari Melnick, Scott A. Armstrong, Warren Shlomchik, Jeff Molldrem, Soldano Ferrone, Crystal Mackall, Laurence Zitvogel, Michael R. Bishop, Sergio A. Giralt, Carl H. June

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug resistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance.

Original languageEnglish (US)
Pages (from-to)709-728
Number of pages20
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Secondary Prevention
Transplants
Education
Recurrence
Neoplasms
Drug Resistance
Epigenomics
Leukemia
Therapeutics
Clonal Evolution
Radiation
Neoplastic Stem Cells
Hematologic Diseases
Biological Factors
Cell Biology
Cause of Death
Stem Cells

Keywords

  • Allogeneic stem cell transplant
  • Biology
  • Cancer stem cells
  • Relapse
  • Resistance

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation : Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. / Cairo, Mitchell S.; Jordan, Craig T.; Maley, Carlo; Chao, Clifford; Melnick, Ari; Armstrong, Scott A.; Shlomchik, Warren; Molldrem, Jeff; Ferrone, Soldano; Mackall, Crystal; Zitvogel, Laurence; Bishop, Michael R.; Giralt, Sergio A.; June, Carl H.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 6, 06.2010, p. 709-728.

Research output: Contribution to journalArticle

Cairo, Mitchell S. ; Jordan, Craig T. ; Maley, Carlo ; Chao, Clifford ; Melnick, Ari ; Armstrong, Scott A. ; Shlomchik, Warren ; Molldrem, Jeff ; Ferrone, Soldano ; Mackall, Crystal ; Zitvogel, Laurence ; Bishop, Michael R. ; Giralt, Sergio A. ; June, Carl H. / NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation : Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 6. pp. 709-728.
@article{7d027903429540bcbde1a8b332c888b5,
title = "NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science",
abstract = "Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug resistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance.",
keywords = "Allogeneic stem cell transplant, Biology, Cancer stem cells, Relapse, Resistance",
author = "Cairo, {Mitchell S.} and Jordan, {Craig T.} and Carlo Maley and Clifford Chao and Ari Melnick and Armstrong, {Scott A.} and Warren Shlomchik and Jeff Molldrem and Soldano Ferrone and Crystal Mackall and Laurence Zitvogel and Bishop, {Michael R.} and Giralt, {Sergio A.} and June, {Carl H.}",
year = "2010",
month = "6",
doi = "10.1016/j.bbmt.2010.03.002",
language = "English (US)",
volume = "16",
pages = "709--728",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

T2 - Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science

AU - Cairo, Mitchell S.

AU - Jordan, Craig T.

AU - Maley, Carlo

AU - Chao, Clifford

AU - Melnick, Ari

AU - Armstrong, Scott A.

AU - Shlomchik, Warren

AU - Molldrem, Jeff

AU - Ferrone, Soldano

AU - Mackall, Crystal

AU - Zitvogel, Laurence

AU - Bishop, Michael R.

AU - Giralt, Sergio A.

AU - June, Carl H.

PY - 2010/6

Y1 - 2010/6

N2 - Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug resistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance.

AB - Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug resistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance.

KW - Allogeneic stem cell transplant

KW - Biology

KW - Cancer stem cells

KW - Relapse

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=77952580739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952580739&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.03.002

DO - 10.1016/j.bbmt.2010.03.002

M3 - Article

VL - 16

SP - 709

EP - 728

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -